Literature review · Tissue recovery

TB-500

TB-500 naming requires particular care. Analytical fragment research and related thymosin-beta-4 experiments are informative, but a supplier label does not establish which sequence is present.

By HeartPep · Reviewed · 3 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

The selected record combines identity analysis, metabolism and fibroblast experiments, plus related-fragment work in mice. These are not clinical evaluations of HeartPep products.

Identity & scope

A 2012 analysis identified acetylated thymosin-beta-4 residues 17-23, Ac-LKKTETQ, in the preparation examined. This is distinct from full-length thymosin beta-4 and from the unacetylated seven-residue fragment.

Catalogue labels covered: TB500; TB-500.

What the research shows

  • The 2024 study found significant wound-assay activity for one metabolite, rather than the parent peptide.
  • Older mouse findings concern a related unacetylated fragment and full-length thymosin beta-4.

Critical interpretation

Why the sequence must come before the claim

TB-500 is a commercial label, while a research paper tests a particular chemical entity. The identity paper is valuable precisely because it measured that entity instead of trusting the label. Acetylation and peptide length distinguish the analysed fragment from both full-length thymosin beta-4 and the unacetylated sequence used in older experiments. For a literature comparison, a supplier sequence and terminal modifications should be checked against the paper before interpreting any biological result. A matching name is insufficient. [1] [3]

The parent peptide and a metabolite are different exposures

The metabolism study provides a reason to resist a simple wound-healing narrative. A significant response for Ac-LKKTE, alongside a nonsignificant parent-peptide result under those assay conditions, leaves open whether metabolism changes activity. It does not prove that the parent is universally inactive, nor that the metabolite will work in an organism. Conversely, absence of cell toxicity within one assay cannot establish systemic safety. Useful follow-up would connect chemically measured exposure with replicated functional outcomes and appropriate controls. [2]

What a transferable experiment would report

Sequence, terminal chemistry, analytical identity, exposure and the tested comparator should travel with every result. Without those details, apparently conflicting findings may concern different molecules or assay conditions. Keeping them visible is more informative than assigning every thymosin-related paper to a single product name. [1] [2] [3]

Limitations & uncertainties

  • A positive result for a metabolite or related sequence cannot be transferred automatically to TB-500 material.
  • No human recovery trial of the supplied preparation is established by these references.

Open research questions

  • What exact sequence, terminal modifications and independent identity measurements accompany each supplied lot?

Selected papers & source records

Download bibliography
Chemical analysisIdentity / technical contextAbstract / record checked

1. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500… (opens in a new tab)

Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P (2012). Drug Testing and Analysis. DOI: 10.1002/dta.1402 (opens in a new tab) · PMID 22962027

Design & population
Chemical analysis of a TB-500-labelled preparation, with synthesis of a reference fragment.
What the study found
Identified Ac-LKKTETQ and developed an analytical detection approach.
Limits on interpretation
Identity work on that sample, not evidence of healing or authentication of another supplier's product.
Cells / laboratoryNamed compoundAbstract / record checked

2. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats… (opens in a new tab)

Rahaman KA, Muresan AR, Min H, et al. (2024). Journal of Chromatography B. DOI: 10.1016/j.jchromb.2024.124033 (opens in a new tab) · PMID 38382158

Design & population
Human serum, enzyme systems, rat urine and fibroblast assays with parent peptide and metabolites.
What the study found
Only Ac-LKKTE showed significant wound-assay activity versus control. Parent and tested metabolites were not cytotoxic under the assay conditions.
Limits on interpretation
An in-vitro wound assay and lack of assay cytotoxicity do not establish human recovery or systemic safety.
Animal studyRelated preparationAbstract / record checked

3. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice (opens in a new tab)

Philp D, Badamchian M, Scheremeta B, et al. (2003). Wound Repair and Regeneration. DOI: 10.1046/j.1524-475x.2003.11105.x (opens in a new tab) · PMID 12581423

Design & population
Dermal-wound experiments in diabetic and aged mice, including full-length thymosin beta-4 and LKKTETQ.
What the study found
Repair-related measures improved in selected models; the unacetylated fragment promoted repair in aged mice.
Limits on interpretation
The tested sequences and models do not establish equivalence to an acetylated catalogue preparation.

Search & review scope

Targeted primary-record searches for TB-500 identity, metabolism and related wound experiments.. Checked 9 November 2026.

Selected sequence-identification and preclinical studies, with exact-versus-related material distinguished.

Selected primary records only, with abstracts checked. Exact identity and a full clinical or retraction-status audit remain outside this bounded review; no absence-of-evidence claim is made.

Recorded search terms
  • TB-500 22962027 Esposito 2012
  • 22962027 Abstract peptide
  • 38382158 TB-500 metabolism

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. TB-500: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/tb-500.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes